FDA restricts use of simvastatin 80 mg

Printer-friendly version
Tags: 
By: 
BHI

The Food and Drug Administration is recommending that physicians restrict prescribing high-dose simvastatin (Zocor, Merck) to patients, given an increased risk of muscle damage [1]. The new FDA drug safety communication, issued today, states that physicians should limit using the 80-mg dose unless the patient has already been taking the drug for 12 months and there is no evidence of myopathy.

Click HERE to read the full FDA safety communication.

Related Articles:

Statins: The Good the Bad and the Ugly by Dr Kent Holtorf, M.D., Founding Director of Bioidentical Hormone Initiative.

 

Resources

BHI Online houses an archive of hormone-related citations for biomedical literature. Also provided are links to PubMed and the NCBI molecular biology resources.
Read more...

Webinars

BHI Online strives to support healthcare professionals through webinars presented by leading experts in their respective fields.
Read more...

Forums

Join the conversation with BHI Online's forums aimed at providing information through communities.
Read more...

Latest News

A selection of stories and articles making headlines in the field of Bioidentical Hormone therapies.
Read more...

Get In Touch

Locate a BHRT doctor, submit an article or just say hello, we'd love to meet you.
Read more...

Sub Page: Side Block 1

Sub Page: Side Block 2

Sub Page: Side Block 3

Sub Page: Side Block 4